1. Introduction {#s0005}
===============

The majority of colorectal cancers (CRC) are caused by a common set of genetic alterations, whereby mutational activation of the WNT pathway represents a key oncogenic initiation event ([@bb0035], [@bb0075]) that remains critical for tumor maintenance and progression ([@bb0070]). Molecular CRC subtypes based upon gene expression patterns have recently been described that likely reflect further genetic and functional heterogeneity and are associated with patient outcome ([@bb0030], [@bb0155], [@bb0210]). Across these data sets, subtypes enriched for mesenchymal and/or stem-cell-like features were associated with poorest outcome ([@bb0030], [@bb0105], [@bb0155], [@bb0210]).

In the intestinal epithelium a gradient of WNT-β-catenin signaling along the crypt-villus axis regulates cellular hierarchy and continuous renewal. High WNT signaling is required for the establishment of intestinal stem cells (ISC) at the crypt bottom, where neighboring Paneth cells constitute the major source of WNT ligands ([@bb0050], [@bb0230]). Numerous observations indicate that analogously, WNT-β-catenin signaling contributes to CRC progression through the maintenance of a stem-cell-like state in a subset of cancer cells ([@bb0005], [@bb0185]).

Canonical WNT signaling output is mediated through a core complex of β-catenin and TCF/LEF transcription factors, which in the intestine is critical for the establishment and proliferation of the normal crypt epithelium, as ablation of either TCF or β-catenin results in prompt crypt loss ([@bb0080], [@bb0120], [@bb0130], [@bb0285]). Whereas the C-terminal domain of β-catenin recruits proteins involved in chromatin remodeling and transcriptional activation that are not β-catenin specific ([@bb0165], [@bb0260]), its N-terminal domain selectively binds Bcl9 or Bcl9l, two likely redundant paralogs which serve as adaptors for additional partner proteins and thereby contribute to further enhancing WNT-β-catenin transcription ([@bb0260]). Despite this apparent auxiliary role, Bcl9 proteins are essential for mouse development, as their ablation is lethal at E10 ([@bb0040]). Yet full blockade of WNT signaling through ablating WNTless (Wls) or Porcupine, which are critical for the secretion of WNT ligands, results in a stronger phenotype with pre-gastrulation lethality at E7 ([@bb0010], [@bb0085]). In mammalian cells overexpression and RNAi gene knock-down experiments confirmed that Bcl9 proteins contribute to, but are not essential for WNT-β-catenin transcription ([@bb0015], [@bb0025], [@bb0110], [@bb0150], [@bb0260]).

Our previous work revealed that ablation of *Bcl9*/*9l* in the adult mouse is dispensable for normal homeostasis of the gastrointestinal epithelium. Though there were no overt anomalies in intestinal homeostasis, mice lacking Bcl9/9l proteins were deficient in epithelial regeneration, as shown in an ulcerative colitis model, pointing to a possible deficiency in ISC expansion and/or maintenance ([@bb0065]). The role of Bcl9/9l in the regulation of stemness properties became overtly apparent in a mouse chemical carcinogenesis model of CRC, which combines exposure to the mutagen azoxymethane (AOM) and the inflammatory agent dextran sulphate sodium (DSS) and serves as a model for constitutively WNT driven human CRC ([@bb0095], [@bb0250]). Ablation of Bcl9/9l proteins resulted in virtual loss of ISC markers, concurrently with marked down-regulation of genes related to EMT and a group of selected WNT targets ([@bb0065]). The control of ISC identity appears to depend upon WNT signaling strength ([@bb0235]). Here we show that the apparently rather subtle tuning role of Bcl9 proteins in WNT β-catenin signaling may by critical for upholding stemness traits in CRC, contributing to the functional heterogeneity among molecular subtypes and determining patient outcome.

2. Materials and Methods {#s0010}
========================

2.1. *APC*/*Kras*-mutant Organoids {#s0015}
----------------------------------

The culture of small intestinal crypts from *Apc*/*Kras* animals has been previously described ([@bb0225], [@bb0280]). Briefly, crypts were isolated and purified, embedded in 50 μl matrigel drops (Corning, 356231) and overlaid with 500 μl organoid medium (Advanced DMEM/F12 (Life Technologies, 11320-082), 2 mM GlutaMAX (Life Technologies, 35050-061), 10 mM HEPES buffer (Sigma, 83264-100ML-F), 0.5 U/ml Penicillin/Streptomycin (Life Technologies, 15070-063), N2 (Life Technologies, 17502-048), B27 (Life Technologies, 12587-010). Organoids were expanded in growth factor supplemented medium for 5 days: 50 ng/ml mEGF (Life Technologies, PMG8041), 100 ng/ml mNoggin (Peprotech, 250--38), 500 ng/ml hRSPO1 (R&D, 4645-RS-025) according to [Fig. 4](#f0020){ref-type="fig"}A. EGF and R-spondin were subsequently removed to select for organoids that had lost the wild-type *Apc* copy. The medium was changed every 2 days. Established mutant lines were passaged every four days by mechanical disruption with a bent P1000 pipette tip. Allograft assays were performed by subcutaneously injecting 50′000 organoid cells mixed 1:1 with 100 μl matrigel. Receiver NOD scid gamma mice (Jackson laboratory, 005557) were bred by the Animal Facility of Epalinges, University of Lausanne, Switzerland. Allograft length and width was determined by caliper measurement, volume was calculated by use of the modified ellipsoid formula: 1 / 2(Length × Width\^2). *In vitro* recombination by R26-CreERT2 was induced by applying 1 μM 4-hydroxytamoxifen (Sigma, H7904) to the culture medium.

2.2. Human CRC Datasets {#s0020}
-----------------------

We made use of the following CRC Gene Expression Omnibus (GEO) databases: [GSE12945](ncbi-geo:GSE12945){#ir0015}, [GSE14333](ncbi-geo:GSE14333){#ir0020}, [GSE17538](ncbi-geo:GSE17538){#ir0025}, [GSE33113](ncbi-geo:GSE33113){#ir0030}, [GSE37892](ncbi-geo:GSE37892){#ir0035}, [GSE39582](ncbi-geo:GSE39582){#ir0040} and [GSE41258](ncbi-geo:GSE41258){#ir0045}, all generated using the Affymetrix HG U133 Plus 2.0 platform. Gene expression data from the PETACC-3 (Pan-European Trials in Alimentary Tract Cancers) trial patients were generated as previously described ([@bb0190]) using the ALMAC Colorectal Cancer DSA platform (Craigavon, Northern Ireland), which is a customized Affymetrix chip that includes 61′528 probe sets mapping to 15′920 unique Entrez Gene IDs. A set of 752 colorectal cancer patients of stage II (108/752) and stage III (644/752) was used here.

2.3. Signature Scores and Survival Analysis {#s0025}
-------------------------------------------

Bcl9/9l-dependent genes with coinciding significant differential expression (log2 fold change of \> 1 and an adjusted p value of \< 0.001) in both the AOM/DSS and *Apc*/*Kras* model were used to identify human homologs (NCBI) and constitute the *BCL9*/*9L*-KO signature. Optimal microarray probe sets were selected according to [@bb0145]. The *BCL9*/*9L*-KO signature is composed of 300 down-regulated and 78 up-regulated human genes. Of these, 215 (71%) down-regulated and 66 (84%) up-regulated genes were contained in the PETACC-3 dataset ([Table S1](#ec0010){ref-type="supplementary-material"}). The *BCL9*/*9L*-KO signature score was defined by subtracting the average of the 300 human homologs down-regulated upon ablation of *Bcl9*/*9l* from the average of the 78 human homologs up-regulated (or 215 down-regulated and 66 up-regulated genes in the PETACC-3 dataset, respectively). Effects of the *BCL9*/*9L*-KO signature on DFS and OS were investigated using Kaplan--Meier estimates with patients categorized into two groups by median split and logrank tests for assessing significance. The Cox proportional hazards model was used to assess the prognostic value of interquartile range (IQR)-standardized values in each patient cohort separately. These survival analyses were performed with the R package *survival*. Meta-analysis and forest plots were done using the *Meta* package in R.

2.4. Association Between Known CRC Subtypes and *BCL9*/*9L*-KO Signature {#s0030}
------------------------------------------------------------------------

The association between the *BCL9*/*9L*-KO signature score standardized by IQR division and subtypes from three studies ([@bb0105], [@bb0155], [@bb0210]) was determined by performing a non-parametric Wilcoxon test to evaluate whether the median of *BCL9*/*9L*-KO signature score for each subtype was different from the median of all patients (2.455313).

3. Results {#s0035}
==========

3.1. RNA Sequencing Reveals a Robust Bcl9/9l-dependent Gene Expression Signature Across Independent Mouse CRC Models {#s0040}
--------------------------------------------------------------------------------------------------------------------

We previously made use of a chemically induced mouse CRC model, which combines exposure to the mutagen azoxymethane (AOM) and the inflammatory agent DSS and serves as a model for constitutively WNT driven human CRC ([@bb0095], [@bb0250]), to investigate the genome-wide impact of *Bcl9*/*9l* ablation on gene expression. Among the striking changes, down-regulation of selected WNT targets, ISC markers and EMT-related genes was particularly noticeable ([@bb0065]). AOM/DSS tumors are typically initiated by β-catenin stabilizing mutations ([@bb0095]). We therefore sought to validate our observations in an independent mouse CRC model driven by loss of *Apc* and oncogenic Kras, which are common oncogenic events in human CRC ([@bb0125]). *Apc*^*1638N*^ and villin-driven *Kras*^*G12V*^ alleles (hereafter *Apc*/*Kras*) were crossed into a homozygous *Bcl*/*9l*^*loxP*/*loxP*^ background ([@bb0065]). *Bcl9*/*9l* deletion in the intestinal epithelium was driven by villin-Cre; mice lacking the villin-Cre transgene served as controls ([Fig. 1](#f0005){ref-type="fig"}A).

To compare Bcl9/9l-dependent phenotypes between the two tumor models we first assessed expression of the genes that were most strongly down-regulated in AOM/DSS tumors lacking Bcl9/9l (hereafter WNT/stemness/EMT reference genes) ([@bb0065]) (Fig. S1A). Similar to AOM/DSS tumors, ablation of *Bcl9*/*9l* in *Apc*/*Kras* colon tumors also resulted in down-regulation of WNT/stemness/EMT reference genes (Fig. S1B). Like AOM/DSS tumors, *Apc*/*Kras* colon tumors also expressed vimentin within tumor cells, albeit to a somewhat lesser extent, and typically the basement membrane underlying vimentin expressing tumor cells appeared to be discontinuous. In both tumor models deletion of *Bcl9*/*9l* resulted in complete abrogation of vimentin expression and restored basement membrane integrity (Fig. S1C, D). These findings clearly suggested that ablation of *Bcl9*/*9l* in *Apc*/*Kras* tumors by and large phenocopies gene expression changes observed in the AOM/DSS model. It is noteworthy that mice bearing *Bcl9*/*9l*-KO *Apc*/*Kras* tumors survived significantly longer than controls, presumably due to a delay in tumor growth (Fig. S1E, F).

To extend the gene expression analysis beyond WNT/stemness/EMT reference genes and establish a robust signature of overlapping changes across these CRC models, we subjected wild-type and *Bcl9*/*9l*-ablated tumor samples from AOM/DSS and *Apc*/*Kras* tumors to RNA sequencing. Bcl9/9l-dependent gene expression changes correlated positively and highly significantly across the two tumor models ([Fig. 1](#f0005){ref-type="fig"}B).

3.2. A *BCL9*/*9L*-knockout Signature is Associated With Improved Progression-free and Overall CRC Patient Survival {#s0045}
-------------------------------------------------------------------------------------------------------------------

The list of genes that were differentially expressed upon ablation of *Bcl9*/*9l* and common to both the RNA sequencing DSS and/DSS and *Apc*/*Kras* tumors comprised 359 down- and 107 up-regulated genes ([Fig. 1](#f0005){ref-type="fig"}C), for which 300 and 78 human homologs, respectively were identified (hereafter *BCL9*/*9L*-KO signature) ([Table S1](#ec0010){ref-type="supplementary-material"}). This *BCL9*/*9L*-KO signature was used to probe the largest public human CRC microarray database (Affymetrix HG U133 Plus 2.0) containing both disease free (DFS) and overall survival (OS) information ([Fig. 1](#f0005){ref-type="fig"}D). Kaplan--Meier analysis of patient samples subdivided into two groups by median split revealed a striking positive association of the *BCL9*/*9L*-KO signature with a more favorable outcome ([Fig. 1](#f0005){ref-type="fig"}D). Additional human CRC databases were probed analogously, including a set of 752 stage II and III samples from the PETACC-3 clinical trial ([@bb0265]), which was generated using a different platform (see Experimental Procedures) and contained high quality clinical follow-up data ([@bb0190]). Consistently, and across different platforms, these analyses corroborated that hazard of relapse or death was highly significantly reduced in patients with tumor profiles associated with the *BCL9*/*9L*-KO signature ([Fig. 1](#f0005){ref-type="fig"}E). Remarkably, the prognostic capacity of the BCL9/9L-KO signature was observed irrespective of tumor stage and independent of molecular parameters as revealed by multivariable analysis ([Table S2](#ec0015){ref-type="supplementary-material"}). Specifically, there was no important effect modulation by other variables such as *BRAF*, *KRAS* or P53 mutations, or the microsatellite instability status.

3.3. Loss of *BCL9*/*9L* Results in Shifting the Stemness to Differentiation Gene Expression Balance Towards Differentiation {#s0050}
----------------------------------------------------------------------------------------------------------------------------

To assess to what extent the prognostic value of the *BCL9*/*9L*-KO signature could be attributed to biologic functions, a wide array of published gene sets relating to intestinal WNT targets, stemness, EMT, and differentiation ([Fig. 2](#f0010){ref-type="fig"}, [Table S3](#ec0020){ref-type="supplementary-material"}) was assessed by gene set enrichment analysis (GSEA) ([@bb0240]) for enrichment in the transcriptomes of *BCL9*/*9L*-KO tumors. Each gene set was assessed individually as exemplified in the two insets, given a score after normalization for the size of the relevant set, and the scores represented as a heatmap ([Fig. 2](#f0010){ref-type="fig"}). Unambiguously, all examined WNT- stemness-, and EMT-related gene sets were negatively enriched, while differentiation-related sets were positively enriched within the transcriptomes of knockout tumors. Remarkably, consistent enrichment scores were observed across the three mouse CRC datasets, i.e. the new RNA sequencing sets from AOM/DSS and *Apc*/*Kras* tumors, and our previously reported Affymetrix microarray data set from DMH/DSS tumors (GSE21576) ([@bb0065]).See [Fig. 1](#f0005){ref-type="fig"}

Importantly, a list comprising all genes common to the individual functional gene sets and the BCL9/9L-KO signature (highlighted in [Table S1](#ec0010){ref-type="supplementary-material"}) proved correlated with patient outcome similar to the entire *BCL9*/*9L*-KO signature (Fig. S2), corroborating that genes comprised in these WNT-, stemness-, EMT-, and differentiation-related gene sets by and large determined its prognostic value.

3.4. The *BCL9*/*9L*-KO Signature is Negatively Associated With High Stemness CRC Subtypes {#s0055}
------------------------------------------------------------------------------------------

Recently, gene expression subtypes of CRC have been reported, which are associated with patient outcome ([@bb0030], [@bb0105], [@bb0155], [@bb0210]). We classified patient samples of the PETACC dataset according to the molecular subtypes defined by [@bb0210] ([Fig. 3](#f0015){ref-type="fig"}A) and [@bb0155]) ([Fig. 3](#f0015){ref-type="fig"}B) and consensus molecular subtypes (CMS) recently reported by the Colorectal Cancer Subtyping Consortium (CRCSC) ([@bb0105]) ([Fig. 3](#f0015){ref-type="fig"}C) and asked to what extent the *BCL9*/*9L*-KO signature was enriched in any of these subtypes. Remarkably, there was a highly significant negative association of the *BCL9*/*9L*-KO signature with the "Stem-like" ([@bb0210]), "C4/CSC" ([@bb0155]) and "CMS4/mesenchymal" ([@bb0105])subtypes that were all characterized by high stemness and/or EMT traits and associated with poor prognosis. *BCL9*/*9L* were expressed above background across all patient samples, and to our knowledge there are no reports on inactivating *BCL9*/*9L* mutations in human tumors. The *BCL9*/*9L*-KO signature was therefore not expected to show strong positive enrichment in any of the other subtypes. It is noteworthy that there was a significant correlation between expression of stemness traits and *BCL9L* and to a lesser extent *BCL9* gene expression levels (Fig. S3A). Accordingly, *BCL9L*, but not *BCL9* expression was significantly correlated to poor outcome in most databases (Fig. S3B).

3.5. *BCL9*/*9L*-ablation in Intestinal Organoids Results in Increased Differentiation and Loss of Tumorigenicity {#s0060}
-----------------------------------------------------------------------------------------------------------------

Recently, conditions have been established allowing to culture and passage intestinal crypt-derived epithelial organoids, which recapitulate the differentiation hierarchy of the small intestinal epithelium ([@bb0225], [@bb0280]). We isolated and cultured *Bcl9*/*9l*-wild-type or *Bcl9*/*9l*-KO small intestinal crypts from *Apc*/*Kras* mice ([@bb0125]), initially in the presence of R-spondin and EGF to stimulate the WNT pathway and expand the cultures as described ([@bb0225]). After five days these growth factors were withdrawn to select for organoids that had lost the remaining wild-type *Apc* allele and had therefore become independent of external WNT stimulation ([@bb0225]) ([Fig. 4](#f0020){ref-type="fig"}A). *Apc*/*Kras*-driven crypt cultures grew mostly as undifferentiated spheres ([Fig. 4](#f0020){ref-type="fig"}B), as described for mutant adenoma-derived organoids ([@bb0225]). In the absence of *Bcl9*/*9l*, however, budding structures resembling normal intestinal organoids ([@bb0230]) were vastly predominant over spherical organoids ([Fig. 4](#f0020){ref-type="fig"}B, C), indicative of a more differentiated state. The *Bcl9*/*9l* status was verified by qRT-PCR and confirmed that there was no selection of escaping *Bcl9*/*9l*-wild-type organoids within *Bcl9*/*9l*-KO cultures (Fig. S4A). Expression of the Bcl9/9l-dependent WNT/stemness/EMT reference genes identified in AOM/DSS colon tumors proved at least in part down-regulated in *Bcl9*/*9*-KO organoids (Fig. S4B--D), despite their small intestinal origin, and conversely, intestinal differentiation markers including villin and keratin 20([@bb0070]) were up-regulated (Fig. S4E). Both wild-type and *Bcl9*/*9l*-KO organoid cultures grew at similar proliferation rates (Fig. S4F), while maintaining their distinct morphology over serial passaging.

Next, we assessed the tumorigenicity of *Bcl9*/*9l*-wild-type or *Bcl9*/*9l*-KO *Apc*/*Kras* organoids in NOD scid gamma mice. Whereas *Bcl9*/*9l*-wild-type subcutaneous allografts grew exponentially, *Bcl9*/*9l*-KO grew only for up to one week before tumors started regressing and became virtually impalpable ([Fig. 4](#f0020){ref-type="fig"}D). Allografts were collected at day 26 after injection when tumors had reached legally admitted size limits. As expected from tumor palpation, wild-type grafts weighed substantially more than *Bcl9*/*9l*-KO counterparts ([Fig. 4](#f0020){ref-type="fig"}E). Macroscopically, some wild-type tumors showed signs of rapid growth with central necrosis, whereas *Bcl9*/*9l*-KO grafts appeared as scar tissue ([Fig. 4](#f0020){ref-type="fig"}F, G). Histologically, wild-type grafts appeared as low-grade adenocarcinomas of intestinal origin, with high resemblance to human CRC, whereas *Bcl9*/*9l*-KO grafts contained only small islets of highly differentiated epithelial structures reminiscent of normal intestinal epithelium, which were surrounded by fibroblastic and inflammatory tissue, compatible with ongoing tumor resorption and concomitant scarring ([Fig. 4](#f0020){ref-type="fig"}H).

3.6. Induced *Bcl9*/*9l* Ablation in Wild-type Intestinal Organoids and Pre-established Tumors Phenocopies Constitutive *Bcl9*/*9l* Inactivation {#s0065}
------------------------------------------------------------------------------------------------------------------------------------------------

The strong association of Bcl9/9l-dependent phenotypes with CRC patient outcome prompted us to address to what extent ablating *Bcl9*/*9l* in wild-type intestinal organoids or pre-established wild-type tumors was able to recapitulate the observed gene expression changes and thereby validate the BCL9/9L-β-catenin interaction as a potential therapeutic target. 4-hydroxytamoxifen (4-OHT) exposure of intestinal organoids derived from of *Apc*/*Kras* mice expressing *R26*-*CreERT* ([@bb0290]) and carrying *Bcl9*/*9l*^*loxP*/*loxP*^ alleles resulted in a rapid shift in the ratio between sphere-like and budding organoids, with progressive disappearance of spheroid structures over 48 h, whereas the proportion of sphere-like organoids remained stable in the untreated controls ([Fig. 5](#f0025){ref-type="fig"}A--C). This phenotype was not observed in 4-OHT treated wild-type spheroids ([Fig. 5](#f0025){ref-type="fig"}C) and correlated with *Bcl9*/*9l* expression levels (Fig. S5A).

Analogously, induction of *Bcl9*/*9l* deletion in pre-established AOM/DSS tumors ([Fig. 5](#f0025){ref-type="fig"}D) resulted, as early as two weeks after tamoxifen-mediated *villin*-*CreERT* activation, in phenotypic changes that by and large recapitulated those observed in constitutively *Bcl9*/*9l*-ablated tumors ([Fig. 5](#f0025){ref-type="fig"}E, F and Fig. S5B). One of the hallmarks of wild-type AOM/DSS tumors is a widespread expression of vimentin within the tumor epithelium paired with discontinuous basement membrane staining (Fig. S1C, upper panel). Upon *Bcl9*/*9l* ablation vimentin expression was completely abrogated and the underlying basement membrane regained normal looking continuity ([@bb0065]) (Fig. S1C, lower panel). These striking phenotypic changes were recapitulated upon conditional *Bcl9*/*9l*-ablation. Tumor areas with residual vimentin expression also showed residual Bcl9 protein, pointing to uneven tamoxifen permeation into tumor tissue and indicating that these Bcl9/9l-dependent phenotypic changes are cell autonomous ([Fig. 5](#f0025){ref-type="fig"}E). Despite residual *Bcl9*/*9l* expression, 14 out of the 18 WNT/stemness/EMT reference genes (Fig. S1A) were down-regulated significantly and proportionally to *Bcl9*/*9l* expression levels ([Fig. 5](#f0025){ref-type="fig"}F).

Taken together these findings demonstrated that Bcl9/9l-dependent phenotypic changes are readily inducible in wild-type organoids as well as pre-established AOM/DSS tumors.

3.7. Genetic Mimicry of a Putative BCL9/9L-β-catenin Inhibitor {#s0070}
--------------------------------------------------------------

To further validate the BCL9/9L-β-catenin interaction as a potential therapeutic target and simulate its pharmacologic inhibition, we combined *Bcl9*/*9l* knock-in alleles, in which only the β-catenin interaction domains (HD2) were deleted ([@bb0040]), with conditional *Bcl9*/*9l*-null alleles ([@bb0065]) to generate *villin*-*CreERT2*-*Bcl9*/*9l*^*loxP*/∆* HD2*^ mice ([Fig. 6](#f0030){ref-type="fig"}A). AOM/DSS tumors were generated prior to deleting the wild-type alleles as described in [Fig. 5](#f0025){ref-type="fig"}D. Similar to tumors with induced *Bcl9*/*9l* ablation ([Fig. 5](#f0025){ref-type="fig"}E, F), tamoxifen administration resulted in loss of vimentin expression in tumor areas that also showed restored basement membrane integrity ([Fig. 6](#f0030){ref-type="fig"}B--D). Accordingly, expression of WNT/stemness/EMT reference genes was reduced proportionally to *Bcl9*/*9l* expression ([Fig. 6](#f0030){ref-type="fig"}E).

Importantly, these experiments unequivocally established that *Bcl9*/*9l*-KO phenotypes observed in CRC models were indeed mediated by the Bcl9/9l-β-catenin complex and were not caused by β-catenin-independent effects of Bcl9/9l as they have recently been reported to occur during lens development ([@bb0040]).

4. Discussion {#s0075}
=============

It is accepted that the cellular hierarchy along the crypt villus axis in the intestinal epithelium is maintained through a WNT signaling gradient ([@bb0050], [@bb0230]), yet the mechanisms underlying the translation of signaling strength into cell type specification remain largely unexplored. Clearly, the identity of ISCs depends critically upon high WNT signaling. A transcriptional response to high WNT ligand concentrations, as they occur in the ISC niche where Paneth cells act as a ligand source, has recently been described to trigger an autoactivation loop of the transcription factor Ascl2, which together with the β-catenin/TCF core complex activates genes that are essential to establishing a stem cell state ([@bb0235]). We previously showed that the BCl9/9L-β-catenin arm of WNT signaling contributes to maintaining this stem cell state ([@bb0065]).

Here we extended these studies and corroborated our observations in an independent mouse CRC model driven by oncogenic Kras and loss of *Apc*, providing a basis for establishing an unbiased, robust signature of Bcl9/9l-dependent genes (Fig. 1A--C).The resulting *BCL9*/*9L*-KO signature of human homologs proved of remarkable prognostic value when used to probe databases of human CRC transcriptomes, clearly revealing that patients with tumor profiles resembling the KO signature had a markedly better prognosis (Fig. 1D, E). GSEA revealed that published gene sets relating to WNT signaling, intestinal stemness, and mesenchymal (EMT) traits were consistently negatively enriched within the individual transcriptomes of *Bcl9*/*9l*-KO mouse tumors, whereas gene sets relating to differentiation were positively enriched ([Fig. 2](#f0010){ref-type="fig"}). Importantly, the subset of genes common to both, these public gene sets and the unbiased *BCL9*/*9L*-KO signature proved of virtually identical prognostic value as the entire KO signature (Fig. S2). Altogether these findings clearly suggest that the prognostic value of the *BCL9*/*9L*-KO signature is by and large due to the attenuation of stemness and mesenchymal, and a concomitant gain in differentiation traits, as a consequence of diminished WNT signaling. Remarkably, the *BCL9*/*9L*-KO signature consistently correlated negatively with subtypes characterized by high stemness traits and poorest outcome ([Fig. 3](#f0015){ref-type="fig"}).

To assess the functional impact of modulating *BCL9*/*9L* expression in an in vitro cell based-model we turned to a panel of human CRC cell lines that we had characterized previously ([@bb0045]). While expression of stemness traits in these cell lines correlated significantly with the recently described poor prognosis features ([@bb0030], [@bb0105], [@bb0155], [@bb0210]), we did not notice any significant correlation with BCL9/9L expression. Also, xenografts of both stemness-high cell lines such as SW480, or more differentiated lines such as HT29 resulted in high-grade tumors with little resemblance to human CRC (data not shown), which typically are of much lower grade. We therefore focused our efforts on a recently described oncogenic intestinal organoid model harboring *Apc* and *Kras* double mutations ([@bb0280]), which upon allografting produced low grade tumors strongly resembling human CRC ([Fig. 4](#f0020){ref-type="fig"}H) and in which we introduced conditional *Bcl9*/*9l* knockout alleles. *Apc*/*Kras*-driven *Bcl9*/*9l*-null intestinal organoids were unable to maintain a sphere-like phenotype and readily evolved towards more differentiated budding structures, thereby completely losing their tumorigenicity in allograft assays ([Fig. 4](#f0020){ref-type="fig"}), in accordance with the notion that *Bcl9*/*9l* in the CRC models is critical for upholding stemness traits.

Collectively, the highly significant impact of *Bcl9*/*9l*-ablation on expression of stemness traits in mouse CRC models paired with the relatively mild phenotype in the unchallenged normal epithelium renders the BCL9/9L-β-catenin interface an attractive potential therapeutic target to target cancer stem cells (CSC) in human CRC. It should be emphasized that *BCL9*/*9L* were expressed across all patient samples (Fig. S2). Pharmacologic inhibition of the BCL9/9L-β-catenin interaction might therefore be of even greater benefit than suggested by the correlation of the BCL9/9L-KO signature with more favorable outcome (Fig. 1D, E).

To further validate the BCL9/9L-β-catenin complex as a potential target we first demonstrated using loxP-flanked alleles and tamoxifen inducible *CreERT2* that *Bcl9*/*9l*-KO phenotypes could be rapidly induced in intestinal organoids and also in pre-established AOM/DSS tumors ([Fig. 5](#f0025){ref-type="fig"}). Our studies consistently made use of compound loss-of function mutants, preventing addressing to what extent Bcl9 and Bcl9l paralogs, which share the same highly conserved homology domains([@bb0020]), are functionally redundant. In most CRC databases stemness traits correlated with BCL9L, but not BCL9 expression, pointing to potentially different roles (Fig. S3B). It is of note, however, that knock-in mice in which the β-catenin binding sites of both Bcl9 and Bcl9l were selectively deleted, phenocopied the loss of the entire proteins, demonstrating unmistakably that the observed loss-of-*Bcl9*/*9l* phenotypes were mediated by β-catenin. This was important as recently β-catenin-independent functions of Bcl9/9l have been discovered ([@bb0040]) ([Fig. 6](#f0030){ref-type="fig"}). Furthermore, these experiments mimicked the action of a potential inhibitor of the BCL9/9L-β-catenin interaction, which in principle appears to be drugable by small molecules ([@bb0060], [@bb0115], [@bb0215]) or peptides ([@bb0245]).

The mechanisms underlying the transcriptional co-activation function of Bcl9/9 l, which appears to be critical for sustaining stemness-related target genes ([Fig. 2](#f0010){ref-type="fig"}, [Table S3](#ec0020){ref-type="supplementary-material"}), but not WNT targets involved in cell proliferation ([@bb0080], [@bb0120], [@bb0130], [@bb0285]), remain to be explored. Bcl9/9l proteins have been described to function as adapters that recruit partner proteins such as Pygopus (Pygo), which eventually may bridge to and modulate the general transcriptional activation complex at the C-terminus of β-catenin ([@bb0140], [@bb0165], [@bb0260]). It remains unclear whether Bcl9/9l exerts its stemness maintenance effects through selective transcriptional modulation of WNT target gene subsets, or through non-selectively enhancing WNT-β-catenin transcriptional output, resulting in threshold-dependent triggering of amplifying loops as described for Ascl2 ([@bb0235]). Pharmacologic inhibition of the interaction of β-catenin with CBP, a component of the general transcriptional activation complex recruited to the C-terminus of β-catenin, has been reported to affect the balance between undifferentiated and differentiated cell states in various tumor models ([@bb0200]), supporting the possibility that general tempering of WNT signaling output might be sufficient for lessening stemness maintenance.

Establishment and maintenance of stemness in the ISC niche requires high WNT signaling. Mutational activation of WNT signaling in CRC results in transcriptional output possibly exceeding WNT responses observed in normal tissues ([@bb0205]). Our findings are compatible with the notion of a direct relation between WNT signaling strength and stemness maintenance. They show that pruning WNT-mediated stemness maintenance as observed upon inactivation of Bcl9/9l affects the regenerative potential in both the normal intestinal epithelium as well in CRC. Whereas the former is tolerated, reducing the regenerative potential of tumors might prove sufficient to significantly impact relapse, in accordance with the CSC model ([@bb0305]). Combining such a stemness tuning strategy with an established CRC treatment protocol therefore represents a promising therapeutic strategy.

The following are the supplementary data related to this article.Fig. S1 Concordant *Bcl9*/*9l*-KO phenotypes in two independent mouse CRC models. (A) AOM/DSS tumors derived from constitutively *Bcl9*/*9l*-null as compared to wild-type gastrointestinal epithelium displayed highly reproducible gene expression changes involving genes associated with WNT signaling, stemness traits and EMT ([@bb0065]). Herein, genes with the strongest down-regulation in constitutively *Bcl9*/*9l*-ablated tumors were assembled into WNT-, stemness- and EMT-core signatures (WNT/stemness/EMT reference genes) that served as a reference for quantitation by qRT-PCR. (Note: 1190002H23Rik has recently been annotated as Rgcc). (B) *Apc*/*Kras* tumors lacking *Bcl9*/*9l* showed a significant down-regulation of 13 out of 18 WNT/stemness/EMT reference genes, thereby largely phenocopying the gene signature shift observed in the AOM/DSS CRC model (Fig. S1A). (C) Hematoxylin and eosin (H&E) staining of wild-type and *Bcl9*/*9l*-null AOM/DSS tumors (left); Vimentin (green) and laminin (red) staining of consecutive sections of wild-type versus *Bcl9*/*9l* deleted AOM/DSS tumors (right). As described previously and reproduced here for comparison ([@bb0065]) *villin*-*Cre*-mediated constitutive deletion of *Bcl9*/*9l* resulted in virtual abrogation of vimentin protein expression in the tumor epithelium that became surrounded by a continuous underlying basement membrane, contrasting with its irregular appearance in wild- type vimentin-positive tumor epithelium. (D) Hematoxylin and eosin (H&E) staining of wild-type and *Bcl9*/*9l*-null *Apc*/*Kras* tumors (left); Vimentin (green) and laminin (red) staining of consecutive sections of wild-type versus *Bcl9*/*9l* deleted *Apc*/*Kras* tumors (right). (E) Median DFS of *Apc*/*Kras* tumor bearing mice. *Bcl9*/*9l* wild-type: 289d; *Bcl9*/*9l*-deleted: 440d; HR 0.31 (95% CI: 0.05--0.51). Mice were sacrificed in pairs, macroscopically inspected for the presence of colon tumors and classified as events or as censored (marks) for survival analysis. (F) Tumor statistics in the *Apc*/*Kras* tumor model. Ablation of *Bcl9*/*9l* resulted in significant, yet modest reduction in tumor size, but had no significant impact on tumor incidence and load. Error bars represent SEM.Fig. S2 Contribution to patient outcome of functionally annotated genes within the *BCL9*/*9L*-KO signature. Forest plots of hazard ratios for DFS and OS for the genes contained in both, the individual gene sets in [Fig. 2](#f0010){ref-type="fig"} and the *BCL9*/*9L*-KO signature. Relevant genes (marked in red in [Table S1](#ec0010){ref-type="supplementary-material"}) contributed similarly to patient outcome as the entire *BCL9*/*9L*-KO signature (Fig. 1E).Fig. S3 Correlation between *BCL9*/*9L*-KO signature and CRC stemness subtypes. (A) Correlation between *BCL9L* and *BCL9* expression levels and the "Stem-like" signature from [@bb0210] in three patient data sets. Correlation and p-value were quantified by Pearson\'s r. (B) *BCL9L*, but not *BCL9* expression was significantly correlated to poor outcome in most databases. Forest plots of HRs for DFS relating to expression of *BCL9* or *BCL9L*.Fig. S4 Expression of WNT/Stemness/EMT reference genes in intestinal organoids. (A--D) QRT-PCR analysis of *Bcl9* and *Bcl9l* transcript levels and of *Bcl9*/*9l*-KO reference WNT/stemness/EMT gene sets (Fig. S1). (E) QRT-PCR analysis of intestinal differentiation markers. (F) Proliferation analysis after 96 h of growth, n = 6 for each genotype.Fig. S5 Recapitulation of constitutive phenotypes upon induced *Bcl9*/*9l* ablation. (A) qRT PCR analysis of *Bcl9* and *Bcl9l* transcript levels in untreated and 4-OHT treated mutant organoids. RNA was collected 7 days after starting 4-OHT treatment. (B) Similar to constitutively *Bcl9*/*9l* ablated AOM/DSS tumors ([@bb0065]), conditional *Bcl9*/*9l* ablation in established AOM/DSS tumors had no significant impact on tumor incidence and proliferation as assessed two weeks after the first tamoxifen injection.Table S1*BCL9*/*9L*-KO signature components. Corresponding probe sets for Affymetrix HG U133 Plus 2.0 datasets and probe sets for the PETACC3 dataset are shown. Genes marked in red are comprised within the individual gene sets in [Fig. 2](#f0010){ref-type="fig"} and were used for the outcome analysis in Fig. S3B.Table S2Univariable and multivariable analysis of the *BCL9*/*9L*-KO signature with regard to patient outcome. Top: univariable and multivariable analysis of DFS and available pathological and molecular markers in GSE39528 patients. Bottom: multivariable analysis of DFS and OS in PETACC3 patients.Table S3Components of GSEA in [Fig. 3](#f0015){ref-type="fig"}. Origin and composition of all individual gene sets that were subjected to GSEA in [Fig. 3](#f0015){ref-type="fig"} ([@bb0055], [@bb0065], [@bb0090], [@bb0100], [@bb0135], [@bb0160], [@bb0170], [@bb0175], [@bb0195], [@bb0220], [@bb0255], [@bb0270], [@bb0275], [@bb0295], [@bb0300]).Table S4List of qRT-PCR primers.Supplementary Material
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![A murine CRC derived *BCL9*/*9L*-KO signature is associated with vastly improved survival in human CRC. (A) *Bcl9*/*9l*-KO and control littermates were subjected to a chemical tumorigenesis protocol as described (see [Materials and Methods](#s0010){ref-type="sec"} and ref. [@bb0180]). Independently, *Apc*/*Kras* alleles were crossed into *Bcl9*/*9l*-KO and wild-type background for inducing WNT-activated CRC ([@bb0110]). (B) RNAseq: Correlation of log2 fold changes between wild-type and *Bcl9*/*9l*-KO AOM/DSS and *Apc*/*Kras* tumors. Pearson\'s r were determined and tested for the hypothesis r = 0. (C) Venn diagram (approximated proportions). Left: genes down-regulated in *Bcl9*/*9l*-KO samples of both *Apc*/*Kras* and AOM/DSS tumors; right: respective up-regulated genes. Human homologs of common mouse genes were selected according to NCBI and corresponding optimal microarray probe sets chosen as described ([@bb0125]), resulting in 300 down-regulated (negatively weighted) and 78 up-regulated (positively weighted) human probe sets. This gene list, hereafter referred to as "*BCL9*/*9L*-KO signature", is shown in [Table S1](#ec0010){ref-type="supplementary-material"} and was used for probing human CRC patient databases. (D) Kaplan--Meier estimates for DFS and OS of CRC patients from one of the largest public human CRC microarray databases (Affymetrix HG U133 Plus 2.0; [GSE17538](ncbi-geo:GSE17538){#ir0005}). DFS and OS of patients with higher (black) or lower (red) expression of the *BCL9*/*9L*-KO signature after subdividing patients according to a median split. (E) Meta-analysis of all CRC patient microarray databases. The relative strength of association of the *BCL9*/*9L*-KO signature with DFS and OS is presented as forest plots of HRs for one inter-quartile unit of the signature score. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)\
A murine CRC derived *BCL9*/*9L*-KO signature is associated with vastly improved survival in human CRC. (A) *Bcl9*/*9l*-KO and control littermates were subjected to a chemical tumorigenesis protocol as described (see [Materials and Methods](#s0010){ref-type="sec"} and ref. [@bb0180]). Independently, *Apc*/*Kras* alleles were crossed into *Bcl9*/*9l*-KO and wild-type background for inducing WNT-activated CRC ([@bb0110]). (B) RNAseq: Correlation of log2 fold changes between wild-type and *Bcl9*/*9l*-KO AOM/DSS and *Apc*/*Kras* tumors. Pearson\'s r were determined and tested for the hypothesis r = 0. (C) Venn diagram (approximated proportions). Left: genes down-regulated in *Bcl9*/*9l*-KO samples of both *Apc*/*Kras* and AOM/DSS tumors; right: respective up-regulated genes. Human homologs of common mouse genes were selected according to NCBI and corresponding optimal microarray probe sets chosen as described ([@bb0125]), resulting in 300 down-regulated (negatively weighted) and 78 up-regulated (positively weighted) human probe sets. This gene list, hereafter referred to as "*BCL9*/*9L*-KO signature", is shown in Table S1 and was used for probing human CRC patient databases. (D) Kaplan--Meier estimates for DFS and OS of CRC patients from one of the largest public human CRC microarray databases (Affymetrix HG U133 Plus 2.0; [GSE17538](ncbi-geo:GSE17538){#ir0010}). DFS and OS of patients with higher (black) or lower (red) expression of the *BCL9*/*9L*-KO signature after subdividing patients according to a median split. (E) Meta-analysis of all CRC patient microarray databases. The relative strength of association of the *BCL9*/*9L*-KO signature with DFS and OS is presented as forest plots of HRs for one inter-quartile unit of the signature score.](gr1){#f0005}

![Loss of *Bcl9*/*9l* is correlated with loss of WNT, EMT and stemness signatures, and increased differentiation traits. Heatmap of normalized GSEA scores in transcriptomes of *Bcl9*/*9l*-KO versus wild-type tumors from three different models. Gene signatures relating to intestinal stemness, WNT, EMT or differentiation were selected from the literature. Each row represents a gene set whose composition and origin are listed in [Table S3](#ec0020){ref-type="supplementary-material"}. Each field depicts a single GSEA of the respective gene signature in the corresponding tumor dataset; insets show examples of a negatively and positively enriched signature, respectively. The color code represents normalized enrichment scores. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)\
Loss of *Bcl9*/*9l* is correlated with loss of WNT, EMT and stemness signatures, and increased differentiation traits. Heatmap of normalized GSEA scores in transcriptomes of *Bcl9*/*9l*-KO versus wild-type tumors from three different models. Gene signatures relating to intestinal stemness, WNT, EMT or differentiation were selected from the literature. Each row represents a gene set whose composition and origin are listed in Table S3. Each field depicts a single GSEA of the respective gene signature in the corresponding tumor dataset; insets show examples of a negatively and positively enriched signature, respectively. The color code represents normalized enrichment scores.](gr2){#f0010}

![Association between the *BCL9*/*9L*-KO signature and stemness subtypes in independent CRC classifications. (A) Association of the *BCL9*/*9L*-KO signature with five CRC subtypes defined by [@bb0170] in 752 patients from the PETACC-3 clinical trial ([@bb0155], [@bb0215]). Patients with *BCL9*/*9L*-KO signature scores below the median are shown in red (*BCL9*/*9L*-WT-like), those with scores above the median are shown in black (*BCL9*/*9L*-KO-like). The insets display the results of a Wilcoxon test evaluating the difference between the median of the *BCL9*/*9L*-KO signature score for each subtype and the median of all patients (2.455313). (B) Analogous analysis to (a) with the CRC subtypes described by [@bb0135]. (C) Analogous analysis to (a) with the consensus molecular subtypes (CMS) described by the Colorectal Cancer Subtyping Consortium ([@bb0090]).](gr3){#f0015}

![Loss of *Bcl9*/*9l* accelerates differentiation of intestinal organoids and abrogates their tumorigenicity. (A) Small intestinal crypts derived from *Bcl9*/*9l*-wild-type or -KO *Apc*/*Kras* mutant mice were cultivated for 5 days as described (see [Materials and Methods](#s0010){ref-type="sec"} and ref. [@bb0180]). Subsequent removal of EGF and R-spondin resulted in selection of organoids with *Apc* loss-of-heterozygosity that grew independently of those growth factors. (B) Morphology of organoids one week after growth factor removal. *Bcl9*/*9l*-wild-type cultures contained a large proportion of spheroids, *Bcl9*/*9l*-KO cultures were virtually devoid of spheroids and contained mostly budding organoids. Scale bars: 100 μm. (C) Quantification of undifferentiated spheroids. (D) Organoid-derived allografts of 50,000 cells injected subcutaneously in NOD scid gamma mice. (E) Weight of allografts collected after 26 days upon reaching the legally admitted tumor size. (F) Resected allografts. Scale bar: 500 μm. (G) Representative picture of a NOD scid gamma mouse exhibiting a large wild-type allograft (right flank) and a small mutant allograft (left flank), consisting mostly of scar tissue. (H) Left panel: Representative images of consecutive sections of a *Bcl9*/*9l*-wild-type allograft. Histopathological analysis revealed a large, moderately differentiated adenocarcinoma of intestinal origin. Broad spectrum cytokeratin staining confirms the large content of viable epithelial cells. Scale bars: 50 μm. Right panel: Representative images of consecutive sections of a *Bcl9*/*9l*-KO allograft. Histopathological analysis revealed small residual and well differentiated islets of epithelial cells of intestinal origin (bottom left). Large parts of the allograft consist of fibroblastic, presumably scar tissue (bottom right) with residual inflammation. Scale bars: 50 μm.](gr4){#f0020}

![Induced loss of *Bcl9*/*9l* recapitulates constitutive phenotypes *in vitro* and *in vivo*. (A) Organoid cultures were established from *Apc*/*Kras Bcl9*/*9l*^*loxP*/*loxP*^ mice carrying a *R26*-*CreERT2* transgene as described in [Fig. 4](#f0020){ref-type="fig"}A. *Bcl9*/*9l* ablation was induced through addition of 4-OHT to the culture medium for 5 days. (B) Representative phase-contrast images 7 days after starting the 4-OHT treatment. Scale bar: 100 μM. (C) Quantification of spheroids in 4-OHT-treated *R26*-*CreERT Apc*/*Kras Bcl9*/*9l*^*loxP*/*loxP*^ cultures as compared to untreated or *R26*-*CreERT*-negative controls. (D) Inducible ablation of Bcl9/9l proteins was investigated *in vivo* in AOM/DSS tumors. The mice were injected intraperitoneally with AOM and subjected to three cycles of DSS administration through the drinking water. Gene deletion was induced when mice showed symptoms of intestinal bleeding, typically 15 weeks after tumor induction. (E) Tamoxifen induced villin-CreERT2-mediated recombination resulted after 14 days in patchy Bcl9/9l deletion, possibly due to uneven tamoxifen permeation. Consecutive tissue sections revealed a remarkable overlap between absence of Bcl9 and vimentin staining and basement membrane integrity; inversely, areas of residual Bcl9 expression (asterisk) correlated with the presence of epithelial vimentin. (F) Induction of *villin*-*CreERT2* resulted in approx. 2-fold decrease of *Bcl9*/*9l* transcripts in bulk tumor mRNA two weeks after the first tamoxifen injection, reflecting approx. 50% chimerism between wild-type and Bcl9/9l-null tumor tissue. 14 out of 18 WNT/stemness/EMT reference genes (Fig. S1A) were significantly down-regulated in these tumor samples, to an extent that was proportional to the decrease of BCL9/9L transcripts.](gr5){#f0025}

![Deletion of the Bcl9/9l-β-catenin interaction domain recapitulates the loss of Bcl9/9l phenotype. (A) A knock-in mouse strain with HD2 deletions of both Bcl9/9l proteins, which were shown to selectively lack the ability to interact with β-catenin ([@bb0040]), was intercrossed with *villin*-*CreERT2*-*Bcl9*/*9l*^*loxP*/*loxP*^ mice ([@bb0060]), generating mice heterozygous for both ∆ HD2 and *Bcl9*/*9l*^*loxP*/*loxP*^ alleles. AOM/DSS tumors were generated as described in [Fig. 5](#f0025){ref-type="fig"}D. Upon tamoxifen administration these tumors became chimeric for tumor tissue, in which either only *Bcl9*/*9l*-∆* HD2* was expressed, or *Bcl9*/*9l*-∆* HD2* was co-expressed with undeleted *Bcl9*/*9l*^*loxP*/*loxP*^ alleles. (B--D) Deletion of the wild-type *Bcl9*/*9l* alleles resulted in virtual abrogation of vimentin (green) in tumor epithelium that became surrounded with a contiguous basement membrane (laminin, red), as observed upon constitutive or induced ablation of Bcl9/9l alleles (Fig. S1 and [Fig. 5](#f0025){ref-type="fig"}). Antibodies recognizing wild-type, but not ∆ HD2 Bcl9 proteins were unavailable. Still, tumor samples with different proportions of wild-type and *Bcl9*/*9l*-deleted tissue suggested a correlation between *Bcl9*/*9l* expression and vimentin protein and transcript levels (C, D). The same tumor samples were used for immunohistochemistry (IHC) and for determining *Bcl9*/*9l* transcript levels (n = 1; mean and SE values relate to technical replicates). Scale bar: 50 μm. (E) Two weeks after the first tamoxifen injection deletion of wild-type *Bcl9*/*9l* in presence of *Bcl9*/*9l*-∆* HD2* resulted in significant down-regulation of 14 out of 18 WNT/stemness/EMT reference genes that was proportional to the residual level of wild-type *Bcl9*/*9l*, thereby phenocopying the induced loss of *Bcl9*/*9l* ([Fig. 5](#f0025){ref-type="fig"}F).](gr6){#f0030}
